ISRG

Intuitive Surgical

$437.75

-1.32%
Nov 16, 2026
Bobby Quantitative Model
Intuitive Surgical develops, manufactures, and markets the da Vinci robotic surgical system for minimally invasive procedures, monetizing its installed base of more than 11,000 systems worldwide (over 6,600 in the US) through a razor-and-blades model of instruments, accessories, and services layered on top of system placements. The company is the undisputed category leader in soft-tissue surgical robotics, with a deep patent moat, surgeon training ecosystem, and hospital workflow entrenchment that have so far blunted competitive entrants such as Medtronic's Hugo platform. The current investor debate centers on three issues: whether procedure growth and system placements can sustain the ~20%+ revenue trajectory as the base gets larger, whether gross and operating margins can recover after a Q3 2026 dip tied to a $450 million legal settlement, and whether a stock down more than 20% year-to-date despite double-digit growth represents a durable de-rating or a buying opportunity in a premium-multiple compounder. Bulls point to the Q3 2026 beat across all key metrics and robust procedure volumes, while bears cite the legal overhang, elevated valuation, and the long-term threat of diversified medtech competitors entering the robotic surgery arena.

People also watch

Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis
Solventum

Solventum

SOLV

Analysis

BobbyInvestment Opinion: Should I buy ISRG Today?

Rating: Buy (accumulate on weakness), with position-sizing discipline. The core thesis is that Intuitive Surgical remains the dominant, zero-debt, ~75% recurring-revenue compounder in soft-tissue surgical robotics, and the Q3 2026 margin collapse to a 19.44% operating margin was driven by a $450 million legal settlement rather than structural deterioration — a view 26 of 30 analysts endorse with a consensus "buy" rating and a $486.57 average target implying roughly +9.7% upside from $443.59. The stock's 21.07% YTD decline against 21.7% revenue growth has compressed the PS multiple to 20.08x, near the bottom of its historical 42.8x–85.8x range, which is the strongest valuation argument in the bull case.

Supporting evidence is concrete: Q3 2026 revenue of $3.049 billion grew 21.7% YoY and rose sequentially from $2.771B (Q1) to $2.892B (Q2), with instruments/accessories ($1.797B) plus services ($482.2M) providing roughly 75% recurring revenue on an installed base above 11,000 systems. Gross margin actually improved to 68.37% in Q3 from 67.78% in Q2 and 66.06% in Q1, confirming the damage was below the gross line, while TTM free cash flow of $3.598 billion on just $113.1 million of capex (over 10x coverage) and a 4.87 current ratio with zero debt underscore financial self-sufficiency. The valuation is the swing factor: 70.80x trailing PE compresses to 35.58x forward on consensus EPS of $17.98, but PS of 20.08x, EV/EBITDA of 49.83x, and a PEG of 3.17 still sit well above large-cap medtech norms, so the market is paying for the earnings inflection to materialize.

The biggest risks that could invalidate the thesis are (1) Q4 failing to restore ~30% operating margins, which would prove the margin hit structural rather than one-time; (2) procedure growth decelerating below high-teens as Medtronic's Hugo and other diversified medtech entrants gain traction; and (3) further multiple compression given the 1.439 beta and -44.0% historical max drawdown. This Buy would upgrade to a higher-conviction stance if Q4 operating margin returns above 30% and PS holds near 20x, and would downgrade to Hold if operating margin stays below 25% for two consecutive quarters or if the stock breaks below the $370 support shelf. Verdict: fairly valued to modestly undervalued on a sales basis relative to its own history, but expensive relative to peers — a premium-quality name that is cheaper than it has been in years, not a bargain.

Sign up to view all

ISRG 12-Month Price Forecast

The forward view is constructive but not euphoric: the business is growing 21.7% with ~75% recurring revenue and a pristine balance sheet, and the sales-based valuation at 20.08x PS is the cheapest it has been in years. The entire debate hinges on whether Q3's 19.44% operating margin was a one-time settlement artifact — if Q4 restores ~30%, the 35.58x forward PE looks reasonable for a 20% grower and the stock should track toward the $486.57 consensus target. The wide $324–$685 analyst range and 1.439 beta argue for measured position sizing rather than aggressive accumulation. I would upgrade to high confidence on a confirmed Q4 margin recovery above 30%, and downgrade to neutral if operating margin stays below 25% for two quarters or the stock breaks the $370 support level.

Historical Price
Current Price $437.75
Average Target $490.00
High Target $685.00
Low Target $324.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $486.57 and implied upside of +11.2% versus the current price.

Average Target

$486.57

34 analysts

Implied Upside

+11.2%

vs. current price

Analyst Count

34

covering this stock

Price Range

$324 - $685

Analyst target range

Buy
26 (77%)
Hold
6 (18%)
Sell
2 (6%)

Coverage is deep and predominantly bullish: 30 analysts rate the stock, with 26 Buy, 6 Hold, and 2 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.76 (where 1.0 is a strong buy). The average target price of $486.57 implies roughly +9.7% upside from the current $443.59, a moderate rather than aggressive signal that reflects how much of the recovery has already occurred — the stock is up 12.44% over three months and 5.56% over one month, so the consensus target is being chased rather than leading. The bullish tilt is reinforced by the October 21, 2026 post-earnings rating round, in which Baird, TD Cowen, RBC, Barclays, Leerink, JP Morgan, Wells Fargo, and BTIG all reiterated Outperform/Buy/Overweight ratings, with only Mizuho (Neutral) and Evercore (In Line) sitting on the sidelines.

The target range of $324.00 to $685.00 is extremely wide — a spread of $361, or roughly 74% of the average target — signaling genuine disagreement about the company's trajectory. The $685 high target implies multiple expansion back toward prior peak valuations plus sustained 20%+ procedure growth and margin recovery toward the mid-30s operating margin seen in Q2 2026, while the $324 low target is essentially at the 52-week low of $328.57 and prices in margin compression, competitive share loss to platforms like Medtronic's Hugo, and a persistent valuation de-rating. The wide dispersion, combined with the recent settlement-driven volatility and the stock's 1.44 beta, argues for position sizing discipline; the consensus EPS estimate of $17.98 (range $17.06–$18.56) and revenue estimate of $19.16 billion (range $18.41–$19.64 billion) suggest analysts broadly expect the Q3 margin dip to be transient, but the low-end targets show that not everyone is convinced.

Drowning in data?

Find the real signal!

Bulls vs Bears: ISRG Investment Factors

The bull case currently holds the stronger evidence: revenue re-accelerated to 21.7% YoY, ~75% of sales are recurring, the balance sheet carries zero debt with $3.6B TTM free cash flow, and 26 of 30 analysts rate the stock Buy with a $486.57 average target. The bear case rests largely on a single quarter's margin collapse (19.4% operating margin from 33.6%) tied to a $450 million settlement, plus a 70.8x trailing PE that assumes a sharp earnings inflection. The single most important tension is whether the Q3 margin hit is truly one-time — if Q4 restores ~30% operating margins, the forward PE of 35.58x looks reasonable for a 20% grower and the de-rating reverses; if margin pressure persists, the premium multiple has further to compress. The wide $324–$685 target range captures this binary, and the stock's 1.44 beta argues for disciplined position sizing while the debate resolves.

Bullish

  • Revenue re-accelerating at 21.7% YoY: Q3 2026 revenue of $3.049 billion grew 21.7% year-over-year versus $2.505 billion in Q3 2025, and the sequential climb from $2.771B (Q1) to $2.892B (Q2) to $3.049B (Q3) shows consistent upward momentum. This re-acceleration on an installed base already exceeding 11,000 systems argues the procedure-volume flywheel is still compounding rather than maturing.
  • Recurring revenue base is ~75% of sales: Instruments and accessories ($1.797B) plus services ($482.2B) contributed roughly $2.28 billion, or about 75% of Q3 revenue, giving high-visibility recurring income layered on top of cyclical system placements. This razor-and-blades mix means procedure growth alone drives the bulk of results even if capital placements slow.
  • Pristine balance sheet with $3.6B FCF: Debt-to-equity is 0.0, the current ratio is 4.87, and cash stood at $3.022 billion at Q3 2026, while TTM free cash flow reached $3.598 billion on capex of just $113.1 million (over 10x capex coverage). The company funded a $2.976 billion Q3 buyback entirely internally, underscoring complete financial self-sufficiency.
  • PS near multi-year lows despite premium: At 20.08x sales, ISRG trades near the bottom of its historical PS range of roughly 42.8x to 85.8x, even as the 70.80x trailing PE sits mid-to-high in its own band. The divergence reflects the settlement depressing the earnings denominator, making the sales-based valuation the strongest bull argument.

Bearish

  • Q3 operating margin collapsed to 19.4%: Operating income fell to $592.6 million (19.44% margin) from $971.9 million (33.60%) in Q2, driven by operating expenses jumping to $1.491 billion including $1.083 billion of SG&A tied to the $450 million legal settlement. Net margin fell to 17.15% from 28.29% sequentially, and investors need to see the ~30% operating margin restored in Q4 to validate the one-time thesis.
  • Trailing PE of 70.8x leaves no room for error: The stock trades at 70.80x trailing earnings, 20.08x sales, 49.83x EV/EBITDA, and a PEG of 3.17 — all well above large-cap medtech norms in the high-single to low-double-digit EV/EBITDA range. The 35.58x forward PE bakes in earnings nearly doubling, so any execution stumble would leave the stock exposed on a trailing basis.
  • Stock down 21.6% over trailing year: Despite double-digit growth, ISRG is down 21.56% over one year and 21.07% YTD, with a -44.0% max drawdown and 1-year relative strength versus SPY of -33.83%. The de-rating signals the market is questioning whether the premium multiple is sustainable even as fundamentals hold.
  • Extreme analyst target dispersion: The $324 to $685 target range spans $361, or roughly 74% of the $486.57 average, signaling genuine disagreement about the trajectory. The $324 low target sits essentially at the $328.57 52-week low and prices in margin compression and competitive share loss, showing not everyone believes the Q3 dip is transient.

ISRG Technical Analysis

ISRG is in a recovery phase within a broader one-year downtrend: the stock is down 21.56% over the trailing year and 21.07% year-to-date, yet has rebounded 12.44% over the past three months and 5.34% over six months. At $443.59, the stock sits roughly 38.2% above its 52-week low of $328.57 and about 26.5% below its 52-week high of $603.88 — translating to approximately 41.9% of its 52-week range, which places it in the lower-middle of the band rather than at either momentum extreme. The -44.0% max drawdown confirms a violent de-rating occurred, and the current positioning suggests the stock is in the repair phase of that drawdown rather than a fresh breakout.

Short-term momentum is clearly positive and diverging constructively from the longer-term trend: the 1-month change of +5.56% and 3-month change of +12.44% both sharply outpace the -21.56% 1-year figure, and relative strength versus SPY is +7.82% over one month and +15.27% over three months, even as the 1-year relative strength remains a dismal -33.83%. This pattern — negative long-term but strongly positive short- and medium-term relative performance — is characteristic of a bottoming/mean-reversion setup rather than a resumption of the downtrend, especially with SPY itself down 2.26% over the past month. The July 2026 capitulation (a drop from $402.33 on July 16 to $345.42 on July 17, followed by a low near $332 on July 23) marked the washout, and the subsequent stair-step recovery to the $440s, including a November 4 spike to $482.10, indicates accumulation. Volume data is reported as zero in the feed, so no volume confirmation can be assessed.

Key technical levels are well defined: support rests at the $328.57 52-week low, with a secondary shelf around $350–$370 where the stock consolidated in August and September 2026, while resistance sits at the $603.88 52-week high, with an intermediate hurdle near the November 4 intraday spike of $482.10. A decisive break above $482 would signal the recovery has matured into a new uptrend and likely open the path toward the $500s, whereas a breakdown below $370 would invalidate the recovery structure and refocus attention on the $328.57 low. With a beta of 1.439, ISRG is roughly 44% more volatile than the market, meaning position sizing should account for amplified drawdowns — the -44.0% max drawdown is a concrete illustration — and a short ratio of 3.06 days suggests short interest is moderate and not a major squeeze catalyst.

Beta

1.44

1.44x market volatility

Max Drawdown

-44.0%

Largest decline past year

52-Week Range

$329-$604

Price range past year

Annual Return

-20.3%

Cumulative gain past year

PeriodISRG ReturnS&P 500
1m+2.6%-3.0%
3m+11.9%-3.6%
6m-2.5%-0.2%
1y-20.3%+10.1%
ytd-22.1%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ISRG Fundamental Analysis

Revenue is growing robustly and, importantly, re-accelerating: Q3 2026 revenue of $3.049 billion rose 21.7% year-over-year versus $2.505 billion in Q3 2025, and the sequential progression from $2.771 billion (Q1 2026) to $2.892 billion (Q2 2026) to $3.049 billion (Q3 2026) shows consistent upward momentum. The segment mix explains the engine: instruments and accessories contributed $1.797 billion, systems $769.1 million, and services $482.2 million in the quarter, meaning recurring instrument/accessory and service revenue (~$2.28 billion, roughly 75% of the total) provides a high-visibility base while system placements add cyclical upside. The 21.7% growth rate against a multi-year trend of high-teens to low-20s growth implies the investment case remains intact — procedure volume growth is compounding on an installed base exceeding 11,000 systems — and supports the consensus revenue estimate of $19.16 billion.

Profitability is strong but showed a notable sequential compression in Q3 2026: net income was $522.8 million on a 17.15% net margin, down sharply from $818.1 million and a 28.29% net margin in Q2 2026 and $821.5 million (29.65%) in Q1 2026, while gross margin slipped to 68.37% from 67.78% in Q2 and 66.06% in Q1 — actually improving at the gross line. The culprit is below the gross profit line: operating income fell to $592.6 million (19.44% operating margin) from $971.9 million (33.60%) in Q2, driven by a jump in operating expenses to $1.491 billion, including $1.083 billion of SG&A and $408.3 million of R&D, consistent with the $450 million legal settlement disclosed in November 2026. The trailing gross margin of 66.00% and operating margin of 29.27% remain best-in-class for medical devices, and the Q3 hit appears one-time rather than structural, but investors will want to see the ~30%+ operating margin restored in Q4.

Balance sheet strength is exceptional: debt-to-equity is 0.0 (no debt), the current ratio is 4.87, and cash stood at $3.022 billion at Q3 2026, giving the company complete internal funding capacity. Free cash flow is powerful — $1.111 billion in Q3 2026 alone and $3.598 billion TTM — with operating cash flow of $1.224 billion against capex of only $113.1 million, a capital-expenditure coverage ratio above 10x. Management is aggressively returning capital, repurchasing $2.976 billion of stock in Q3 2026 (versus $320.3 million in Q2), which explains the $2.894 billion financing outflow, while ROE of 16.02% and ROA of 11.85% confirm high-quality capital deployment; the only blemish is a PCF ratio of 66.7x, reflecting how richly the market values that cash generation.

Quarterly Revenue

$3.0B

2026-09

Revenue YoY Growth

+21.7%

YoY Comparison

Gross Margin

68.4%

Latest Quarter

Free Cash Flow

$3.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Instruments and Accessories
Services
Systems

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ISRG Overvalued?

Because ISRG is solidly profitable (Q3 2026 net income of $522.8 million; TTM net margin 28.38%), the PE ratio is the appropriate primary metric. The stock trades at 70.80x trailing earnings but only 35.58x forward earnings — a roughly 50% compression that implies the market expects earnings to nearly double, consistent with consensus EPS of $17.98 versus the current run-rate. That gap is the crux of the valuation debate: investors are paying a steep trailing multiple for a business whose earnings are expected to inflect sharply, so any execution stumble would leave the stock exposed on a trailing basis.

On every secondary metric ISRG screens as expensive: PS of 20.08x, EV/Sales of 12.94x, EV/EBITDA of 49.83x, PB of 11.34x, and a PEG of 3.17, all well above typical medical-device sector norms (large-cap medtech generally trades in the high-single to low-double-digit EV/EBITDA and low-to-mid single-digit PS range). The premium is defensible on quality grounds — 66% gross margins, 29% operating margins, zero debt, and a dominant robotic-surgery franchise — but a PEG above 3 signals the market is paying up for growth, and the 35.58x forward PE leaves limited room for multiple expansion without continued 20%+ revenue growth.

Against its own history, the current 70.80x trailing PE sits near the upper end of its recent band: historical quarterly PE readings ranged from roughly 42.9x (Q2 2026) and 49.9x (Q1 2026) up to 77.2x (Q3 2024) and 84.7x (Q4 2021), while PS of 20.08x compares with historical PS readings that ranged from about 42.8x to 85.8x — meaning the current PS is actually near multi-year lows even as the PE sits mid-to-high in its range. That divergence reflects the earnings hit from the settlement depressing the PE denominator; on a sales basis, the stock is cheaper than it has been in years, which is the strongest argument for the bulls and the key tension in the valuation picture.

PE

70.8x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 43x~85x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

49.8x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the Q3 2026 margin shock and the valuation's dependence on a sharp earnings inflection. Operating margin fell to 19.44% from 33.60% sequentially as operating expenses jumped to $1.491 billion, including $1.083 billion of SG&A tied to the $450 million legal settlement, dragging net margin to 17.15% from 28.29%. The 70.80x trailing PE versus 35.58x forward PE means the market is paying for earnings to nearly double to consensus EPS of $17.98, so any delay in margin recovery would leave the stock exposed on a trailing basis. Revenue concentration in the da Vinci franchise and its ~75% recurring instrument/service mix is a strength but also a single-platform dependency, and the PEG of 3.17 signals little cushion for slower procedure growth.

Market and competitive risks are amplified by valuation and volatility. At 20.08x sales, 49.83x EV/EBITDA, and 11.34x book, ISRG trades at a steep premium to large-cap medtech norms, leaving it vulnerable to multiple compression if growth decelerates or rates stay elevated. Medtronic's Hugo robot is gaining traction, and diversified medtech entrants into soft-tissue robotics could erode share over time, while the $450 million settlement highlights litigation exposure. With a beta of 1.439, ISRG is roughly 44% more volatile than the market, and the -44.0% max drawdown is a concrete illustration of how violently a premium multiple can de-rate; the stock's -33.83% one-year relative strength versus SPY shows this risk has already begun to materialize.

In a worst-case scenario, persistent margin compression, a slower-than-expected earnings inflection, and competitive share loss would combine to force the multiple back toward the low end of its historical band. The realistic downside is anchored by the $328.57 52-week low and the $324 analyst low target, implying roughly -26% to -27% from the current $443.59. A deeper adverse path — where Q4 fails to restore ~30% operating margins and procedure growth slips below high-teens — could revisit the July 2026 washout near $332, and in an extreme de-rating toward the $324 low target an investor could lose approximately -27% from current levels. The -44.0% historical max drawdown shows that in a genuine sentiment reversal, losses could exceed the 52-week-low anchor.

FAQ

On a risk/reward basis ISRG offers a moderate but asymmetric setup: the $486.57 average analyst target implies about +9.7% upside from $443.59, while the $324 analyst low target and $328.57 52-week low imply roughly -26% to -27% downside, so the reward is smaller than the tail risk unless the margin recovery materializes. The quality underpinning is real — 21.7% YoY revenue growth, ~75% recurring revenue, zero debt, a 4.87 current ratio, and $3.598 billion of TTM free cash flow — and the 20.08x PS multiple sits near the bottom of its historical range, which limits how much valuation compression is left. The biggest downside risk is that the Q3 operating margin collapse to 19.44% proves structural rather than tied to the $450 million settlement, which would leave the 70.80x trailing PE badly exposed. It is a good buy for long-horizon investors comfortable with a 1.439 beta who can accumulate in tranches and tolerate a retest of the $350–$370 shelf, but it is not a low-risk entry for short-term traders or anyone who needs the Q4 margin proof before committing capital.